Skip to content
value.today

PellePharm, Inc.

🇺🇸 Menlo Park, California, USABiotechnologyFounded 2012
Total raised
$18 M
5 rounds on record
Latest round
$8 M
Jun 2018
First round on record
Oct 2014
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of PellePharm, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2018$8 MNo. 5$2 to $10 million

PellePharm, Inc.: Raise no. 5, Jun 2018

Investors in this round

7 investors had bought by the notice of Jul 3, 2018: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sanuj Ravinddran, M.D. · Executive Officer, Director, Promoter
  • Ervin Epstein, M.D. · Director
  • Frank McCormick, Ph.D. · Director
  • Jean Y. Tang, M.D., Ph.D. · Director
  • Neil Kumar, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sanuj Ravinddran, M.D., President and CEO. Source: SEC Form D, newest notice filed Jul 3, 2018. Read the notice at the SEC.

equitySEC
Jun 2016$3 MNo. 4$2 to $10 million

PellePharm, Inc.: Raise no. 4, Jun 2016

Investors in this round

4 investors had bought by the notice of Aug 17, 2016: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $8 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ervin Epstein, M.D. · Executive Officer, Director
  • Mark De Souza, Ph.D. · Executive Officer, Director
  • Frank McCormick, Ph.D. · Director
  • Jean Tang, M.D., Ph.D. · Director
  • Neil Kumar, PH.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Sale and issuance of shares of Series B-2 Preferred”

Signed by Mark De Souza, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 17, 2016. Read the notice at the SEC.

equitySEC
Jul 2015$5 MNo. 3$2 to $10 million

PellePharm, Inc.: Raise no. 3, Jul 2015

Investors in this round

1 investor had bought by the notice of Jul 24, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ervin Epstein · Executive Officer, Director
  • Mark de Souza · Executive Officer
  • Jean Tang · Director
  • Katrin Andreasson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark de Souza, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 24, 2015. Read the notice at the SEC.

equitySEC
Mar 2015$2 MNo. 2Under $2 million

PellePharm, Inc.: Raise no. 2, Mar 2015

Investors in this round

8 investors had bought by the notice of Apr 21, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ervin Epstein · Executive Officer, Director
  • Mark de Souza · Executive Officer
  • Jean Tang · Director
  • Katrin Andreasson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ervin Epstein, President. Source: SEC Form D, newest notice filed Apr 21, 2015. Read the notice at the SEC.

equitySEC
Oct 2014$1 MNo. 1Under $2 million

PellePharm, Inc.: Raise no. 1, Oct 2014

Investors in this round

6 investors had bought by the notice of Oct 24, 2014: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ervin Epstein · Executive Officer, Director
  • Jean Tang · Director
  • Katrin Andreasson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ervin Epstein, President. Source: SEC Form D, newest notice filed Oct 24, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • PellePharm, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2018).

    SEC Form D · Jul 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2018

That is all the official record says: PellePharm, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of PellePharm, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by PellePharm, Inc.
NameRoleNamed in
Sanuj Ravinddran, M.D.Executive officerJul 2018
Ervin Epstein, M.D.Executive officerAug 2016
Mark De Souza, Ph.D.Executive officerAug 2016
Ervin EpsteinExecutive officerJul 2015
Mark de SouzaExecutive officerJul 2015
Ervin Epstein, M.D.DirectorJul 2018
Frank McCormick, Ph.D.DirectorJul 2018
Jean Y. Tang, M.D., Ph.D.DirectorJul 2018
Neil Kumar, Ph.D.DirectorJul 2018
Sanuj Ravinddran, M.D.DirectorJul 2018
Jean Tang, M.D., Ph.D.DirectorAug 2016
Mark De Souza, Ph.D.DirectorAug 2016
Neil Kumar, PH.D.DirectorAug 2016
Ervin EpsteinDirectorJul 2015
Jean TangDirectorJul 2015
Katrin AndreassonDirectorJul 2015
Sanuj Ravinddran, M.D.PromoterJul 2018